The Latest Cardiac and Vascular News
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian markets, today announced that CAMZYOS® (mavacamten) has received marketing approval for the treatment […]
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint China National Medical Products Administration (NMPA) accepted mavacamten New Drug Application (NDA) with priority review Mavacamten commercial launch preparations continue in China, supported by the […]
SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that CAMZYOS® (mavacamten) has received marketing approval for the […]
• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in […]
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing, with data expected mid-year 2023 Phase 3 registrational trial of TP-03 in Chinese patients with Demodex blepharitis ongoing, with data expected in the fourth quarter […]
Enrollment completed in registrational Phase 3 EXPLORER-CN trial of mavacamten, with data expected mid-2023 Mavacamten patient education and physician awareness activities underway in China with inclusion in HCM treatment guidelines, disease awareness campaign launch, and key commercial leadership hired Pivotal […]
• Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy Chinese volunteers, expected to support registration of mavacamten in China SHANGHAI, China and PRINCETON, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a […]
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM ongoing LianBio’s partner, Tarsus, announced […]
Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten in obstructive hypertrophic cardiomyopathy to support regulatory approval in China SHANGHAI, China and PRINCETON, […]
SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Chen to the […]
